It’s been two months since Abbott’s new biosensing wearable Lingo, designed to enable consumers to monitor their metabolic health, made its debut in the United Kingdom. And thus far, the reception in that test market has been “extremely positive,” Olivier Ropars, division vice president of Abbott’s Lingo Biowearables told Medtech Insight at the HLTH conference last week.
Abbott’s Metabolic Biowearable Gets ‘Extremely Positive’ UK Reception; Next Up, US Filing
“We’re so steeped in scientific and medical expertise that we never really learned how to talk to or with regular people,” says Abbott CEO Robert Ford.
Medtech Insight caught up with Abbott’s division VP of Lingo Biowearables at HLTH to learn more about its recent UK launch and future plans.
